Navigation Links
Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
Date:4/30/2013

DUBLIN, April 30, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.

The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.

Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.

For each company profiled, the following information is provided:

  • Detailed Technology Description
  • Development Status / Pipeline Products
  • Patents and Publications
  • Partnership and Funding Opportunities
  • Business Development & Licensing Contact

Examples of Technologies Presented

  • Mini-pump for subcutaneous delivery of IV medications
  • Targeted nanoparticle micelles
  • Antibody-targeted liposomes
  • Abuse-deterrent delivery system
  • Dry powder particle processing technology
  • Oral capsule technology for biologics
  • Nanovesicle delivery system for delivery across the blood-brain barrier
  • Timed-release intra-ocular implant device
  • Non-invasive aerosol device for brain drug delivery
  • Extracellular drug conjugate technology
  • Nanoparticles and novel device for CNS and inner ear drug delivery
  • Next-generation auto-injector technology
  • Nanopolymer drug conjugates
  • Microneedle patch system
  • Pocket-sized ultrasound delivery device
  • Biodegradable, topical drug patch

62 Company Profiles (partial listing)

  • Affinity Therapeutics
  • Aquarius Biotechnologies
  • Axxia Pharmaceuticals
  • Blend Therapeutics
  • Clearside Biomedical
  • Cristal Delivery BV
  • DLVR Therapeutics
  • EnduRx Pharmaceuticals
  • Ekteino Laboratories
  • Extend Biosciences
  • Inspiro Medical
  • KAER Biotherapeutics
  • Lauren Sciences, LLC
  • LyoGo LLC
  • Orbis Biosciences
  • ProLynx LLC
  • Prometheon Pharma, LLC
  • Qrono, Inc.
  • scPharmaceuticals, LLC
  • Vaxxas

+ 42 More Companies

Reasons to Buy

- Identify early stage delivery technologies that will potentially enable the delivery of your therapeutic compound
- Learn about investment opportunities with emerging companies, to gain access to promising, early stage technologies
- Identify novel drug delivery formulations available for partnering, to enhance your product portfolio

For more information visit Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
4. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity
7. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
8. Researchers peek at the early evolution of sex chromosomes
9. Discuss Early Results of the DIAN Trial at CBIs 6th Annual Alzheimers Drug Development Summit
10. Early career distinction: Prestigious award recognizes physicists work in electron dynamics
11. JCI early table of contents for Sept. 4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... that exhibits both viscous and elastic characteristics when deformed, which is identical to ... properties to gently absorb compressive forces and return to its natural state along ...
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 ... "Biorefinery Products: Global Markets" report to their offering. ... The ... from $466.6 Billion in 2016 at a CAGR of 8.9%, ... of energetic and non-energetic bioproducts into seven major product segments: ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
Breaking Biology Technology:
(Date:3/1/2017)...  Aware, Inc. (NASDAQ: AWRE), a leading supplier of ... Moberg has resigned, effective March 3, 2017, as ... and Treasurer of Aware citing a desire to retire.  ... of the Board of Directors of Aware. ... and co-President, General Counsel has been named Chief Executive ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
Breaking Biology News(10 mins):